FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767967816> ?p ?o ?g. }

• W2767967816 endingPage "635" @default.
• W2767967816 startingPage "622" @default.
• W2767967816 abstract "Abstract Introduction We are developing a second generation 8‐OH quinoline (2‐(dimethylamino) methyl‐5, 7‐dichloro‐8‐hydroxyquinoline [PBT2, Prana Biotechnology]) for targeting amyloid β (Aβ) in Alzheimer's disease (AD). In an earlier phase IIa, 3 month trial, PBT2 lowered cerebrospinal fluid Aβ by 13% and improved cognition (executive function) in a dose‐related fashion in early AD. We, therefore, sought to learn whether PBT2 could alter the Aβ‐PET signal in subjects with prodromal or mild AD, in an exploratory randomized study over a 12‐month phase in a double‐blind and a 12‐month open label extension phase trial design. Methods For inclusion, the usual clinical criteria for prodromal or probable AD, Mini–Mental State Examination ≥20, and global Pittsburgh compound B (PiB)‐PET standardized uptake volume ratio (SUVR) >1.7 were used. As this was an exploratory study, we included contemporaneous matched control data from the Australian Imaging Biomarker and Lifestyle Study (AIBL). Other measures included fluorodeoxyglucose‐positron emission tomography, magnetic resonance imaging volumetrics, blood Aβ biomarkers, and cognition and function. Results Forty subjects completed the first 12‐month double‐blind phase (placebo = 15, PBT2 = 25), and 27 subjects completed the 12‐month open label extension phase (placebo = 11, PBT2 = 16). Overall, PTB2 250 mg/day was safe and well tolerated. The mean PiB‐PET SUVR at baseline was 2.51 ± 0.59. After adjusting for baseline SUVR, in the double‐blind phase, the placebo group showed a nonsignificant decline in PiB‐PET SUVR, whereas the PBT2 group declined significantly ( P = .048). Subjects who did not enter or complete the extension study had a significantly higher 12‐month Aβ‐PET SUVR (2.68 ± 0.55) compared with those who completed (2.29 ± 0.48). Both groups differed significantly from the rate of change over 12 months in the AIBL control group. In the open label 12‐month extension study, the PiB‐SUVR stabilized. There were no significant differences between PBT2 and controls in fluorodeoxyglucose‐positron emission tomography, magnetic resonance imaging volumetrics, blood Aβ biomarkers, or cognition/function over the course of the double‐blind phase. Discussion There was no significant difference between PBT2 and controls at 12 months, likely due to the large individual variances over a relatively small number of subjects. PBT2 was associated with a significant 3% PiB‐PET SUVR decline in the double‐blind phase and a stabilization of SUVR in the open‐label phase. From this exploratory study, we have learned that the entry criterion of SUVR should have been set at ≥ 1.5 and <2.0, where we know from the AIBL study that subjects in this band are accumulating Aβ in a linear fashion and that subjects who withdrew from this type of study have much higher SUVRs, which if not taken into account, could distort the final results. Because of large individual variations in SUVR, future studies of PBT2 will require larger numbers of subjects (n > 90 per arm) over a longer period (18 months or more). Further evaluation of higher doses of PBT2 in earlier stages of AD is warranted. Trial Registration ACTRN 12611001008910 and ACTRN 12613000777796." @default.
• W2767967816 created "2017-11-17" @default.
• W2767967816 creator A5000808429 @default.
• W2767967816 creator A5006122087 @default.
• W2767967816 creator A5022818431 @default.
• W2767967816 creator A5025220020 @default.
• W2767967816 creator A5027376897 @default.
• W2767967816 creator A5033361414 @default.
• W2767967816 creator A5033772486 @default.
• W2767967816 creator A5040456565 @default.
• W2767967816 creator A5047385288 @default.
• W2767967816 creator A5058052951 @default.
• W2767967816 creator A5061043399 @default.
• W2767967816 creator A5064285976 @default.
• W2767967816 creator A5064879007 @default.
• W2767967816 creator A5083402471 @default.
• W2767967816 creator A5089807849 @default.
• W2767967816 date "2017-11-01" @default.
• W2767967816 modified "2023-09-30" @default.
• W2767967816 title "A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study" @default.
• W2767967816 cites W1582477554 @default.
• W2767967816 cites W1585083630 @default.
• W2767967816 cites W1824074994 @default.
• W2767967816 cites W1921787609 @default.
• W2767967816 cites W1964747897 @default.
• W2767967816 cites W1970004454 @default.
• W2767967816 cites W1992165389 @default.
• W2767967816 cites W2000786089 @default.
• W2767967816 cites W2025983435 @default.
• W2767967816 cites W2050386832 @default.
• W2767967816 cites W2051489981 @default.
• W2767967816 cites W2051516838 @default.
• W2767967816 cites W2053361295 @default.
• W2767967816 cites W2055659156 @default.
• W2767967816 cites W2058690573 @default.
• W2767967816 cites W2059963640 @default.
• W2767967816 cites W2063808031 @default.
• W2767967816 cites W2069440543 @default.
• W2767967816 cites W2092896299 @default.
• W2767967816 cites W2107979600 @default.
• W2767967816 cites W2109593507 @default.
• W2767967816 cites W2113518834 @default.
• W2767967816 cites W2116709840 @default.
• W2767967816 cites W2117047219 @default.
• W2767967816 cites W2118421222 @default.
• W2767967816 cites W2128124856 @default.
• W2767967816 cites W2129497119 @default.
• W2767967816 cites W2130622073 @default.
• W2767967816 cites W2133541776 @default.
• W2767967816 cites W2134711807 @default.
• W2767967816 cites W2150481150 @default.
• W2767967816 cites W2151384687 @default.
• W2767967816 cites W2156220037 @default.
• W2767967816 cites W2157110881 @default.
• W2767967816 cites W2253163222 @default.
• W2767967816 cites W2510806376 @default.
• W2767967816 cites W2576842289 @default.
• W2767967816 cites W2603308917 @default.
• W2767967816 cites W950120787 @default.
• W2767967816 doi "https://doi.org/10.1016/j.trci.2017.10.001" @default.
• W2767967816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5702880" @default.
• W2767967816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29201996" @default.
• W2767967816 hasPublicationYear "2017" @default.
• W2767967816 type Work @default.
• W2767967816 sameAs 2767967816 @default.
• W2767967816 citedByCount "56" @default.
• W2767967816 countsByYear W27679678162018 @default.
• W2767967816 countsByYear W27679678162019 @default.
• W2767967816 countsByYear W27679678162020 @default.
• W2767967816 countsByYear W27679678162021 @default.
• W2767967816 countsByYear W27679678162022 @default.
• W2767967816 countsByYear W27679678162023 @default.
• W2767967816 crossrefType "journal-article" @default.
• W2767967816 hasAuthorship W2767967816A5000808429 @default.
• W2767967816 hasAuthorship W2767967816A5006122087 @default.
• W2767967816 hasAuthorship W2767967816A5022818431 @default.
• W2767967816 hasAuthorship W2767967816A5025220020 @default.
• W2767967816 hasAuthorship W2767967816A5027376897 @default.
• W2767967816 hasAuthorship W2767967816A5033361414 @default.
• W2767967816 hasAuthorship W2767967816A5033772486 @default.
• W2767967816 hasAuthorship W2767967816A5040456565 @default.
• W2767967816 hasAuthorship W2767967816A5047385288 @default.
• W2767967816 hasAuthorship W2767967816A5058052951 @default.
• W2767967816 hasAuthorship W2767967816A5061043399 @default.
• W2767967816 hasAuthorship W2767967816A5064285976 @default.
• W2767967816 hasAuthorship W2767967816A5064879007 @default.
• W2767967816 hasAuthorship W2767967816A5083402471 @default.
• W2767967816 hasAuthorship W2767967816A5089807849 @default.
• W2767967816 hasBestOaLocation W27679678161 @default.
• W2767967816 hasConcept C126322002 @default.
• W2767967816 hasConcept C126838900 @default.
• W2767967816 hasConcept C142724271 @default.
• W2767967816 hasConcept C143409427 @default.
• W2767967816 hasConcept C15744967 @default.
• W2767967816 hasConcept C204787440 @default.
• W2767967816 hasConcept C27081682 @default.
• W2767967816 hasConcept C2775842073 @default.
• W2767967816 hasConcept C2777415128 @default.

• next